Verastem Halts RAMP 203 Trial to Prioritize KRAS G12D Inhibitor Development in Advanced NSCLC

Reuters2025-12-30

<a href="https://laohu8.com/S/VSTM">Verastem</a> Halts RAMP 203 Trial to Prioritize KRAS G12D Inhibitor Development in Advanced NSCLC

Verastem Oncology announced the discontinuation of its RAMP 203 Phase 1/2 clinical trial evaluating avutometinib in combination with LUMAKRAS™ (sotorasib) and defactinib for advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC). The decision follows an interim data evaluation and reflects a shift in focus toward the clinical development of VS-7375, a KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors. According to the company, RAMP 203 enrolled 66 patients at the recommended Phase 2 dose, with efficacy data showing a 40% overall response rate and a median progression-free survival of 11.1 months among 30 G12C-inhibitor treatment-naïve patients. These results were available as of the November 26, 2025, data cutoff. Verastem also noted ongoing development of avutometinib and defactinib in other indications, including a Phase 3 confirmatory trial in recurrent low-grade serous ovarian cancer and a trial in advanced pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251229302295) on December 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2595589087?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-30 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595589087","market":"nz","top_or_hot":-1,"title":"Verastem Halts RAMP 203 Trial to Prioritize KRAS G12D Inhibitor Development in Advanced NSCLC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Halts RAMP 203 Trial to Prioritize KRAS G12D Inhibitor Development in Advanced NSCLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Verastem Oncology announced the discontinuation of its RAMP 203 Phase 1/2 clinical trial evaluating avutometinib in combination with LUMAKRAS™ (sotorasib) and defactinib for advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC). The decision follows an interim data evaluation and reflects a shift in focus toward the clinical development of VS-7375, a KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors. According to the company, RAMP 203 enrolled 66 patients at the recommended Phase 2 dose, with efficacy data showing a 40% overall response rate and a median progression-free survival of 11.1 months among 30 G12C-inhibitor treatment-naïve patients. These results were available as of the November 26, 2025, data cutoff. Verastem also noted ongoing development of avutometinib and defactinib in other indications, including a Phase 3 confirmatory trial in recurrent low-grade serous ovarian cancer and a trial in advanced pancreatic cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251229302295) on December 29, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Halts RAMP 203 Trial to Prioritize KRAS G12D Inhibitor Development in Advanced NSCLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Halts RAMP 203 Trial to Prioritize KRAS G12D Inhibitor Development in Advanced NSCLC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-30 05:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Halts RAMP 203 Trial to Prioritize KRAS G12D Inhibitor Development in Advanced NSCLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Verastem Oncology announced the discontinuation of its RAMP 203 Phase 1/2 clinical trial evaluating avutometinib in combination with LUMAKRAS™ (sotorasib) and defactinib for advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC). The decision follows an interim data evaluation and reflects a shift in focus toward the clinical development of VS-7375, a KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors. According to the company, RAMP 203 enrolled 66 patients at the recommended Phase 2 dose, with efficacy data showing a 40% overall response rate and a median progression-free survival of 11.1 months among 30 G12C-inhibitor treatment-naïve patients. These results were available as of the November 26, 2025, data cutoff. Verastem also noted ongoing development of avutometinib and defactinib in other indications, including a Phase 3 confirmatory trial in recurrent low-grade serous ovarian cancer and a trial in advanced pancreatic cancer.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251229302295) on December 29, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VSTM","symbol_name":"Verastem","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL2VCdN2:1","article_id":"2595589087","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595589087","pubTimestamp":1767042082,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Verastem Oncology announced the discontinuation of its RAMP 203 Phase 1/2 clinical trial evaluating avutometinib in combination with LUMAKRAS  and defactinib for advanced KRAS G12C-mutated non-small cell lung cancer . The decision follows an interim data evaluation and reflects a shift in focus toward the clinical development of VS-7375, a KRAS G12D  inhibitor, in advanced NSCLC and other solid tumors. According to the company, RAMP 203 enrolled 66 patients at the recommended Phase 2 dose, with efficacy data showing a 40% overall response rate and a median progression-free survival of 11.1 months among 30 G12C-inhibitor treatment-nave patients. These results were available as of the November 26, 2025, data cutoff. Verastem also noted ongoing development of avutometinib and defactinib in other indications, including a Phase 3 confirmatory trial in recurrent low-grade serous ovarian cancer and a trial in advanced pancreatic cancer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VSTM":"Verastem","BK4139":"生物科技"},"translate_title":"Verastem停止RAMP 203试验，优先开发晚期非小细胞肺癌的KRAS G12D抑制剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":0.9},"content_text":"Verastem Halts RAMP 203 Trial to Prioritize KRAS G12D Inhibitor Development in Advanced NSCLC\n    \n\n        Verastem Oncology announced the discontinuation of its RAMP 203 Phase 1/2 clinical trial evaluating avutometinib in combination with LUMAKRAS™ (sotorasib) and defactinib for advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC). The decision follows an interim data evaluation and reflects a shift in focus toward the clinical development of VS-7375, a KRAS G12D (ON/OFF) inhibitor, in advanced NSCLC and other solid tumors. According to the company, RAMP 203 enrolled 66 patients at the recommended Phase 2 dose, with efficacy data showing a 40% overall response rate and a median progression-free survival of 11.1 months among 30 G12C-inhibitor treatment-naïve patients. These results were available as of the November 26, 2025, data cutoff. Verastem also noted ongoing development of avutometinib and defactinib in other indications, including a Phase 3 confirmatory trial in recurrent low-grade serous ovarian cancer and a trial in advanced pancreatic cancer.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251229302295) on December 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595589087","isCrawlerRequest":true}